

## Correspondence

*Psychological Medicine*, 38 (2008)  
doi:10.1017/S0033291707002255

### Letter to the Editor

#### Should we advise patients with serious mental illness to stop using cannabis?

Advising patients with serious mental illness to stop their cannabis intake tends to be unpopular with patients, and also with some psychiatrists. Patients enjoy using cannabis, and can perceive it as being therapeutically beneficial. Thus, their reluctance to stop their cannabis intake is understandable. The argument of psychiatrists and other mental health-care professionals against giving such advice is that since the effect of cannabis on psychosis is nothing or negligible, psychiatry must not portray itself as a 'killjoy' profession, because this could lead to fewer mentally ill patients trusting psychiatrists to help them. On the other hand, Macleod (2007), in his excellent commentary on Degenhardt *et al.* (2007), considers that trying to prevent or reduce cannabis use amongst the mentally ill patients is justifiable, even when one considers its apparently small effect on psychosis. He supports this opinion by underlining that cannabis is not only deleterious on psychosis, but it is also a contributing factor to physical health problems. I agree with the reasons he gave but I also believe that this approach is totally justifiable also on the basis of the effect of cannabis on psychosis only. As clinicians, we should provide the best possible holistic treatment to our patients. Since schizophrenia is a 'dreadful illness that is substantially unexplained and ineffectively treated' (Macleod, 2007), it poses unique challenges. Thus, any measure that can contribute towards relieving suffering, however negligible is its effect, should be considered seriously. Also, one must not forget that such measures do not influence patients uniformly, and a negligible measure for one patient can be a significant one for another patient. How can we convince more psychiatrists and more mental health-care professionals to advise patients to stop their cannabis intake? An obvious need is to conduct research into the efficacy of different ways of persuading patients with serious mental illness to refrain from using cannabis.

#### Declaration of Interest

None.

### References

- Degenhardt L, Tennant C, Gilmour S, Schofield D, Nash L, Hall W, McKay D (2007). The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study. *Psychological Medicine* 37, 927–934.
- Macleod J (2007). Cannabis use and symptom experience amongst people with mental illness: a commentary on Degenhardt *et al.* *Psychological Medicine* 37, 913–916.

ANTON GRECH

Consultant Psychiatrist,  
Mount Carmel Hospital, Attard, Malta  
(Email: anton.grech@onvol.net)

*Psychological Medicine*, 38 (2008)  
doi:10.1017/S0033291707002267

### Letter to the Editor

#### Drawing conclusions about cannabis and psychosis

The renewed interest in the association between cannabis and mental illness is well reflected in three articles and a commentary in volume 37, number 7, of *Psychological Medicine*. In some ways it is surprising that there still seems so much diffidence regarding the drawing of definite conclusions from what is an increasingly converging literature. One reason for this may be the confusion regarding predisposing, precipitating, and perpetuating effects of delta-9-tetrahydrocannabinol (THC) on psychosis, as well as a reliance on positive symptoms of psychosis as the hallmark of schizophrenia. In sum:

- (1) There is no doubt that THC can precipitate psychosis: indeed, it does so reliably in a dose-response way, and arguably anyone could manifest positive psychotic symptoms given a large enough dose (see Castle & Solowij, 2004).
- (2) The individual liability to the manifestation of positive symptoms on exposure to THC depends upon individual 'psychosis proneness', as shown nicely in a non-clinical sample by Verdoux and colleagues (Verdoux, 2004). Clearly people with schizophrenia are very 'psychosis prone' and they would be expected to manifest positive symptoms at even low dose, similar to someone with diabetes eating sugar (see Linszen *et al.* 2004). The study of Degenhardt *et al.* (2007) that found only a modest